Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [18F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in setting of clinical trials.
|Title of host publication||Nuclear Oncology|
|Subtitle of host publication||From Pathophysiology to Clinical Applications|
|Publisher||Springer International Publishing|
|Number of pages||41|
|State||Published - Oct 27 2017|
- Response to therapy